Newswise News from Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) Latest news from Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) on Newswise en-us Copyright 2024 Newswise Newswise News from Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) 115 31 / /images/newswise-logo-rss.gif First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer /articles/first-patients-dosed-in-phase-2-platform-clinical-trial-testing-novel-immunotherapy-combinations-in-highly-malignant-ovarian-cancer/?sc=rsin /articles/first-patients-dosed-in-phase-2-platform-clinical-trial-testing-novel-immunotherapy-combinations-in-highly-malignant-ovarian-cancer/?sc=rsin Wed, 11 May 2022 08:00:37 EST A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment. Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA)